Transplantation: Can sirolimus prevent skin cancer in transplant recipients?

Nature Reviews Nephrology

Volumn 6, Issue 11, 2010, Pages 639-641

  Geissler, Edward K ^a   Schlitt, Hans J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS; TUMOR ANTIGEN;

ANGIOGENESIS; ANKLE EDEMA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CAUSE OF DEATH; CELL INVASION; CLINICAL ASSESSMENT; CLINICAL STUDY; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; METASTASIS INHIBITION; NON MELANOMA SKIN CANCER; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SHORT SURVEY; SKIN CANCER; SKIN DEFECT; SKIN EXAMINATION; TREATMENT DURATION; TUMOR CELL; ULTRAVIOLET RADIATION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SIROLIMUS; SKIN NEOPLASMS;

EID: 78049373649     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.130     Document Type: Short Survey

References (10)

1. Hojo, M. et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397, 530-534 (1999).
2. Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 8, 128-135 (2002).
3. Ulrich, C., Kanitakis, J., Stockfleth, E. & Euvrard, S. skin cancer in organ transplant recipients\where do we stand today? Am. J. Transplant 8, 2192-2198 (2008).
4. Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K. & suthanthiran, M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73, 1565-1572 (2002).
5. Geissler, E. K., Schlitt, H. J. & Thomas, G. mTOR, cancer and transplantation. Am. J. Transplant. 8, 2212-2218 (2008).
6. Stallone, G. et al. sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352, 1317-1323 (2005).
7. de Fijter, J. W. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol. Dial. Transplant. 22 (suppl. 1), i23-i26 (2007).
8. Campistol, J. M. et al. sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 17, 581-589 (2006).
9. Salgo, R. et al. switch to a sirolimus-based mmunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am. J. Transplant. 10, 1385-1393 (2010).
10. Rostaing, L. & Kamar, N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J. Nephrol. 23, 133-142 (2010).